Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data KAZIA THERAPEUTICS LTD files with the SEC in its annual reports.
In AUD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.41
0.25
0.12
15.2
0
0
2.31
0.04
Research and development
9.89
11.1
9.77
6.48
9.49
14.5
20.2
15.6
17.4
7.33
Selling, general and administrative
5.76
8.53
5.6
3.79
3.69
7.02
5.11
8.58
13.6
8.72
Interest expense
0.77
Interest income
0.1
0.07
0.04
0
0.02
0.01
0.07
Pre-tax income
-12.2
-10.9
-6.34
-10.6
-12.8
-8.9
-25.4
-20.7
-27
-22.4
Income tax
-0.2
-0.31
-0.3
-0.3
-0.48
-0.37
-0.27
-0.27
-1.75
Net income to minority interests
-0.09
Net income
-12.1
-10.7
-6.04
-10.3
-12.5
-8.42
-25
-20.5
-26.8
-20.7
EPS, basic
-0.03
-0.02
-0.12
-0.18
-0.17
-0.07
-0.19
-0.11
-0.10
-0.04
EPS, diluted
-0.03
-0.02
-0.12
-0.18
-0.17
-0.07
-0.19
-0.11
-0.10
-0.04
Balance sheet
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
33.5
14.5
5.96
5.43
8.76
27.6
7.36
5.24
1.66
4.35
Receivables
4.26
2.54
1.71
1.35
0.08
0.09
3.9
3.9
0.1
Total current assets
19.5
9.26
7.52
10.7
29.4
9.45
10.8
6.15
4.93
Property, plant and equipment
0.59
0.49
0
Intangible assets
0.82
15.9
14.6
13.5
12.4
21
19.1
17.3
15.4
1.09
Total assets
35.9
28.2
21.2
23.1
58.1
35.9
28.1
21.6
6.06
Accounts payable
1.87
2.07
1.76
3.49
4.93
3.76
4.33
15.1
10.1
Short-term debt
1.84
1.8
0.63
0.4
Total current liabilities
5.38
3.89
1.9
5.07
8.33
6.73
7.57
25.8
14.1
Total liabilities
10.6
8.93
6.98
8.94
20.2
17.6
16
31.6
14.4
Retained earnings
-171
-14.6
-24.9
-36.2
-44.2
-68.6
-89.1
-115
-135
Shareholders' equity
25.3
19.2
14.2
14.1
37.9
18.3
12.1
-10
-8.3
Total equity
33.9
25.3
19.2
14.2
14.1
37.9
18.3
12.1
-10
-8.3
Total liabilities and equity
35.9
28.2
21.2
23.1
58.1
35.9
28.1
21.6
6.06
Cash flow statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-12.2
-10.7
-6.04
-10.3
-12.5
-8.42
-25
-20.5
-26.8
-20.7
Depreciation and amortization
0.64
1.42
1.55
1.08
1.08
Cash from operations
-12
-11.4
-8.66
-6.71
-8.81
-9.11
-22.8
-15.2
-9.58
-13.3
Capital expenditures
-0.52
-0.01
Cash from investing
-0.52
-7.12
0.15
2.36
-2.37
0
0
Debt issued
0
0
0.78
0
Debt repaid
0
0
-0.37
0
Stock issued
0.85
3.82
12.1
28.1
3.73
13
2.91
11.8
Dividends paid
0
0
0
0
0
0
Cash from financing
0.78
-0.02
3.82
12.1
28.1
3.73
13
5.99
16
Exchange rate effect
0.8
-0.43
0.01
0.02
-0.18
1.18
0.06
0.01
-0.02
Free cash flow
-12.5
-11.4
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Pre-tax margin
-53,448.0%
Pre-tax income / revenue.
Net margin
-49,290.0%
Net income / revenue.
Operating cash flow margin
-31,614.0%
Cash from operations / revenue.
Return on assets (ROA)
-149.8%
Net income / average total assets.
R&D / revenue
17,443.0%
Research and development expense / revenue.
SG&A / revenue
20,762.0%
Selling, general and administrative expense / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-98.2%
Revenue vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-71.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-44.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-23.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.35x
Current assets / current liabilities.
Quick ratio
0.32x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.31x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-A$0.04
Net income per basic share, as reported (split-adjusted).
What was KAZIA THERAPEUTICS LTD's revenue in fiscal 2025?
KAZIA THERAPEUTICS LTD reported revenue of A$42.0K for fiscal 2025, 98.2% lower than the year before.
Was KAZIA THERAPEUTICS LTD profitable in fiscal 2025?
No. It reported a net loss of A$20.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.